vs
Side-by-side financial comparison of Boxlight Corp (BOXL) and CytomX Therapeutics, Inc. (CTMX). Click either name above to swap in a different company.
Boxlight Corp is the larger business by last-quarter revenue ($29.3M vs $18.7M, roughly 1.6× CytomX Therapeutics, Inc.). CytomX Therapeutics, Inc. runs the higher net margin — -0.8% vs -21.1%, a 20.3% gap on every dollar of revenue. On growth, Boxlight Corp posted the faster year-over-year revenue change (-19.2% vs -25.7%). Over the past eight quarters, CytomX Therapeutics, Inc.'s revenue compounded faster (-15.9% CAGR vs -23.1%).
Boxlight Corp is a global provider of interactive technology solutions, including interactive flat panel displays, projectors, collaborative software, and classroom technology accessories. It primarily serves K-12 and higher education institutions, as well as corporate and government customers across North America, Europe, and Asia Pacific, focusing on enhancing learning and work collaboration efficiency.
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
BOXL vs CTMX — Head-to-Head
Income Statement — Q3 FY2025 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $29.3M | $18.7M |
| Net Profit | $-6.2M | $-154.0K |
| Gross Margin | 29.1% | — |
| Operating Margin | -13.4% | -6.9% |
| Net Margin | -21.1% | -0.8% |
| Revenue YoY | -19.2% | -25.7% |
| Net Profit YoY | -102.0% | 97.6% |
| EPS (diluted) | $-1.88 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | $29.3M | — | ||
| Q2 25 | $30.9M | $18.7M | ||
| Q1 25 | — | $50.9M | ||
| Q4 24 | $24.0M | $38.1M | ||
| Q3 24 | $36.3M | $33.4M | ||
| Q2 24 | $38.5M | $25.1M | ||
| Q1 24 | $37.1M | $41.5M | ||
| Q4 23 | $38.8M | $26.6M |
| Q3 25 | $-6.2M | — | ||
| Q2 25 | $-4.7M | $-154.0K | ||
| Q1 25 | — | $23.5M | ||
| Q4 24 | $-16.7M | $18.9M | ||
| Q3 24 | $-3.1M | $5.7M | ||
| Q2 24 | $-1.5M | $-6.5M | ||
| Q1 24 | $-7.1M | $13.8M | ||
| Q4 23 | $-17.7M | $837.0K |
| Q3 25 | 29.1% | — | ||
| Q2 25 | 35.0% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 30.6% | — | ||
| Q3 24 | 33.8% | — | ||
| Q2 24 | 37.7% | — | ||
| Q1 24 | 34.5% | — | ||
| Q4 23 | 31.7% | — |
| Q3 25 | -13.4% | — | ||
| Q2 25 | -12.7% | -6.9% | ||
| Q1 25 | — | 44.4% | ||
| Q4 24 | -67.6% | 46.4% | ||
| Q3 24 | -2.4% | 12.3% | ||
| Q2 24 | 3.2% | -33.7% | ||
| Q1 24 | -9.7% | 28.1% | ||
| Q4 23 | -42.8% | -2.3% |
| Q3 25 | -21.1% | — | ||
| Q2 25 | -15.3% | -0.8% | ||
| Q1 25 | — | 46.2% | ||
| Q4 24 | -69.6% | 49.6% | ||
| Q3 24 | -8.4% | 17.2% | ||
| Q2 24 | -3.8% | -26.0% | ||
| Q1 24 | -19.1% | 33.3% | ||
| Q4 23 | -45.5% | 3.1% |
| Q3 25 | $-1.88 | — | ||
| Q2 25 | $-1.53 | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $-87.29 | — | ||
| Q3 24 | $-1.72 | — | ||
| Q2 24 | $-0.92 | — | ||
| Q1 24 | $-0.76 | — | ||
| Q4 23 | $-19.01 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $11.8M | $49.0M |
| Total DebtLower is stronger | $36.7M | — |
| Stockholders' EquityBook value | $-19.5M | $119.9M |
| Total Assets | $99.6M | $175.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $11.8M | — | ||
| Q2 25 | $7.6M | $49.0M | ||
| Q1 25 | — | $47.6M | ||
| Q4 24 | $8.0M | $38.1M | ||
| Q3 24 | $10.5M | $40.6M | ||
| Q2 24 | $7.5M | $43.2M | ||
| Q1 24 | $11.8M | $36.2M | ||
| Q4 23 | $17.3M | $17.2M |
| Q3 25 | $36.7M | — | ||
| Q2 25 | $39.0M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $37.1M | — | ||
| Q3 24 | $38.8M | — | ||
| Q2 24 | $40.3M | — | ||
| Q1 24 | $38.5M | — | ||
| Q4 23 | $40.2M | — |
| Q3 25 | $-19.5M | — | ||
| Q2 25 | $-20.6M | $119.9M | ||
| Q1 25 | — | $25.0M | ||
| Q4 24 | $-12.9M | $-456.0K | ||
| Q3 24 | $6.5M | $-23.5M | ||
| Q2 24 | $7.5M | $-31.2M | ||
| Q1 24 | $9.1M | $-31.7M | ||
| Q4 23 | $16.8M | $-47.4M |
| Q3 25 | $99.6M | — | ||
| Q2 25 | $99.2M | $175.1M | ||
| Q1 25 | — | $98.5M | ||
| Q4 24 | $115.3M | $120.5M | ||
| Q3 24 | $142.9M | $139.0M | ||
| Q2 24 | $141.3M | $159.2M | ||
| Q1 24 | $142.4M | $184.7M | ||
| Q4 23 | $161.8M | $201.8M |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 5.93× | — | ||
| Q2 24 | 5.38× | — | ||
| Q1 24 | 4.23× | — | ||
| Q4 23 | 2.40× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $1.3M | $-15.8M |
| Free Cash FlowOCF − Capex | — | $-15.8M |
| FCF MarginFCF / Revenue | — | -84.6% |
| Capex IntensityCapex / Revenue | — | 0.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-77.7M |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $1.3M | — | ||
| Q2 25 | — | $-15.8M | ||
| Q1 25 | — | $-21.0M | ||
| Q4 24 | $1.6M | $-19.9M | ||
| Q3 24 | $5.2M | $-20.7M | ||
| Q2 24 | $-5.4M | $-19.5M | ||
| Q1 24 | $-1.9M | $-26.0M | ||
| Q4 23 | $3.3M | $-22.0M |
| Q3 25 | — | — | ||
| Q2 25 | — | $-15.8M | ||
| Q1 25 | — | $-21.2M | ||
| Q4 24 | — | $-20.0M | ||
| Q3 24 | — | $-20.7M | ||
| Q2 24 | — | $-19.6M | ||
| Q1 24 | — | $-26.2M | ||
| Q4 23 | — | $-22.2M |
| Q3 25 | — | — | ||
| Q2 25 | — | -84.6% | ||
| Q1 25 | — | -41.6% | ||
| Q4 24 | — | -52.5% | ||
| Q3 24 | — | -62.1% | ||
| Q2 24 | — | -78.2% | ||
| Q1 24 | — | -63.1% | ||
| Q4 23 | — | -83.5% |
| Q3 25 | — | — | ||
| Q2 25 | — | 0.1% | ||
| Q1 25 | — | 0.2% | ||
| Q4 24 | — | 0.2% | ||
| Q3 24 | — | 0.1% | ||
| Q2 24 | — | 0.4% | ||
| Q1 24 | — | 0.3% | ||
| Q4 23 | — | 1.0% |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -0.89× | ||
| Q4 24 | — | -1.05× | ||
| Q3 24 | — | -3.61× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -1.89× | ||
| Q4 23 | — | -26.24× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BOXL
| Products | $27.4M | 93% |
| Services | $2.0M | 7% |
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
